As an example, RRx-001 is expected to be evaluated for several different indications: 1) small cell lung cancer (SCLC) 2) mucositis 3) radiation countermeasure 4) leukemia and myelodysplastic syndrome 5) NLRP3 inflammasome-related diseases. Here, NLRP3 is linked to small cell lung carcinoma.